Vienna, Austria: – Recombinant protein specialist manufacturer enGenes Biotech GmbH (enGenes) has announced a new collaboration with the Technical University of Vienna (TU Wien) to apply the company’s proprietary enGenes-eXpress™ technology to integrative bioprocess development for biosimilar production.
The project, funded by the Wiener Wirtschaftsagentur (Vienna Business Agency), has considerable implications for biosimilars companies, holding out the prospect of decreased manufacturing costs for complex molecules, reduced time-to-market and diminished development risks. The mid-term goal is to provide cell lines and manufacturing processes with certified quality parameters such as biological activity in bioassays or comparative biosimilarity to originator.
For more information follow https://www.pharmaceutical-networking.com/new-project-applies-engenes-x-press-to-biosimilars/
Kommentare